Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
164 hedge funds and large institutions have $972M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 67 increasing their positions, 48 reducing their positions, and 18 closing their positions.
631% more call options, than puts
Call options by funds: $636K | Put options by funds: $87K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
40% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 48
35% more capital invested
Capital invested by funds: $720M → $972M (+$253M)
4% more funds holding
Funds holding: 157 → 164 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$38.8M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$8.56M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$8.31M |
| 4 |
AC
Armistice Capital
New York
|
+$7.5M |
| 5 |
BlackRock
New York
|
+$6.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$27.6M |
| 2 |
DM
Deerfield Management
New York
|
-$14.2M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$12.6M |
| 4 |
NLVP
New Leaf Venture Partners
New York
|
-$8.07M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.27M |
DCPH Hedge Fund Activity: Q4 2023 in Review
164 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q4 2023, worth a combined $972M — up 35% from $720M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new DCPH positions and 18 closed out — a net gain of 8 holders — while 67 added to existing stakes and 48 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $38.8M. The largest seller was Braidwell, cutting an estimated $27.6M.
- 164 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q4 2023, up from 157 in Q3 2023.
- Funds reported $972M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q4 2023, up 35% quarter-over-quarter.
- 26 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q4 2023 and 18 closed out, a net change of +8 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q4 2023 was Morgan Stanley, an estimated $38.8M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q4 2023 was Braidwell, an estimated $27.6M sold.
Based on aggregated 13F filings for Q4 2023.